Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol)

1 site for NCT05104567

HRAS Mutation, +2 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +3 more conditions

cetuximab, +2 more drugs

immunotherapy, +1 more type

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

1 site for NCT04853043

APC Mutation, +4 more biomarkers

Colorectal Adenocarcinoma

cetuximab

targeted therapy

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

9 sites for NCT05039177

BRAF V600E, +2 more biomarkers

Colorectal Carcinoma

cetuximab, +3 more drugs

targeted therapy

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

51 sites for NCT03190915

CBL Loss, +8 more biomarkers

Juvenile Myelomonocytic Leukemia, +1 more condition

trametinib

targeted therapy

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

1 site for NCT05168904

BRAF Mutation, +6 more biomarkers

Acute Myeloid Leukemia, +3 more conditions

CYC065

targeted therapy

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

4 sites for NCT05054374

ARAF Mutation, +18 more biomarkers

Breast Carcinoma, +1 more condition

fulvestrant, +1 more drug

hormone therapy, +1 more type

CRAFT: The NCT-PMO-1602 Phase II Trial

4 sites for NCT04551521

AKT1 Amplification, +78 more biomarkers

Malignant Solid Tumor

alectinib, +6 more drugs

immunotherapy, +1 more type

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

39 sites for NCT04417621

BRAF Codon 600 Missense, +1 more biomarker

Cutaneous Melanoma

LTT462, +3 more drugs

targeted therapy

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

1 site for NCT04734990

ASXL1 Loss, +7 more biomarkers

Chronic Myelomonocytic Leukemia-0, +3 more conditions

azacitidine, +1 more drug

chemotherapy, +1 more type

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.

19 sites for NCT04835805

NRAS Mutation

Cutaneous Melanoma

atezolizumab, +2 more drugs

immunotherapy, +1 more type